ANTENGENE-B(06996): ATG-201 for the treatment of B cell-mediated autoimmune diseases has received HREC approval for the Phase I ATTRACT study in Australia.

07:00 25/08/2026

Deqi Medical-B (06996) announced that the Board of Directors is pleased to declare that the Phase I ATTRACT study of ATG-201 (a CD19/CD3 bispecific T cell engager antibody developed by the group for the treatment of B cell-related autoimmune diseases) has obtained approval from the Human Research Ethics Committee (HREC) of Australia, and the process of submitting the Clinical Trial Notification (CTN) to the Therapeutic Goods Administration (TGA) has been completed.

ANTENGENE-B (06996) announced that the company's board of directors is pleased to report that the Phase I ATTRACT study for ATG-201, a CD19/CD3 bispecific T cell engager antibody developed independently by the group for the treatment of B cell-related autoimmune diseases, has received approval from the Human Research Ethics Committee (HREC) in Australia and has completed the process of submitting the Clinical Trial Notification (CTN) to the Therapeutic Goods Administration (TGA).

SpaceX (SPCX.US) has moved up the launch date of its first batch of Starmind AI satellites to the end of 2027, partnering with NVIDIA Corporation to accelerate the development of orbital data centers.

China Securities Co., Ltd.: Pay attention to the accelerated certification pace and investment opportunities of domestic semiconductor material companies in the context of import substitution.

SpaceXAI will use NVIDIA Corporation (NVDA.US) Vera CPU to accelerate agent AI applications.

China Securities Co., Ltd.: Pay attention to the accelerated certification pace and investment opportunities of domestic semiconductor material companies in the context of import substitution.

SpaceXAI will use NVIDIA Corporation (NVDA.US) Vera CPU to accelerate agent AI applications.